Weekly Recap: ZDd raises MRD—negative CR in RRMM and Camzyos PDUFA

Bristol-Myers Squibb Company (NYSE:BMY) reported Phase 3 EXCALIBER—RRMM interim wins for ZDd over DVd in RRMM with higher MRD—negative CR and ORR but more neutropenia, awaits Sept. 30 FDA PDUFA on Camzyos for ages 12—17 with adolescent safety mirroring adults, and is lobbying to retain China licens…